Published in J Immunol on May 15, 1995
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med (1997) 1.53
The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am (2000) 1.52
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol (1996) 1.49
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol (1996) 1.43
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine (1997) 1.32
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther (2008) 1.16
The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol (1996) 1.13
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology (1998) 1.07
Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol (1999) 1.06
The promise of nucleic acid vaccines. Gene Ther (2000) 1.05
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res (1996) 1.00
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother (1999) 0.89
The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol (1995) 0.85
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother (1997) 0.85
Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst (1998) 0.85
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst (1999) 0.84
Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther (2010) 0.81
Tumor antigens discovery: perspectives for cancer therapy. Mol Med (1997) 0.79
Oncolytic virus therapy for cancer. Oncolytic Virother (2013) 0.78
Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTrial10-CFTR2. J Physiol (1997) 0.78
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J (1986) 11.41
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 3.58
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology (1987) 3.53
Vaccinia virus: a tool for research and vaccine development. Science (1991) 3.21
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A (1988) 2.34
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol (1993) 2.25
A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today (1993) 2.02
Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature (1987) 1.99
Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol (1993) 1.94
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol (1988) 1.81
Cancer vaccines. Immunol Today (1993) 1.67
Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol (1990) 1.62
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 1.59
New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res (1990) 1.58
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Tumour prevention and rejection with recombinant vaccinia. Nature (1987) 1.47
Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature (1986) 1.45
Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev (1992) 1.34
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol (1991) 1.31
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A (1991) 1.22
Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine (1993) 1.21
Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses (1991) 1.19
Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice. J Immunol (1991) 1.16
Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med (1985) 1.16
Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology (1993) 1.14
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol (1993) 1.06
Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res (1990) 1.06
Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J Immunol (1993) 1.03
Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A (1988) 0.99
Skin test to assess virus-specific cytotoxic T-cell activity. Proc Natl Acad Sci U S A (1992) 0.93
Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine (1990) 0.92
Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. Vaccine (1990) 0.91
In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery (1994) 0.88
Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Genet Dev (1993) 0.87
Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Immunol Cell Biol (1990) 0.86
In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gene Ther (1994) 0.82
Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother (1993) 0.79
Vaccinia-interleukin 2 recombinant virus or exogenous interleukin 2 does not alter the magnitude or immune response gene defects of the cytotoxic T-cell response to vaccinia virus in vivo. Scand J Immunol (1989) 0.78
The sequence of the human genome. Science (2001) 101.55
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Sequence and genomic organization of Norwalk virus. Virology (1993) 6.25
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Anaesthesia (2014) 4.07
Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc (2000) 3.99
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem (2001) 3.64
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol (1998) 3.32
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. J Biol Chem (1994) 2.92
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med (1998) 2.84
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
The topography of awareness: a classification of intra-operative cognitive states. Anaesthesia (2012) 2.61
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol (1990) 2.45
Are nonspecific practice guidelines potentially harmful? A randomized comparison of the effect of nonspecific versus specific guidelines on physician decision making. Health Serv Res (2000) 2.45
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Interplay of electron-lattice interactions and superconductivity in superconductivity in Bi2Sr2CaCu2O8+delta. Nature (2006) 2.40
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Establishment, maintenance and description of cell lines from the tick Ixodes scapularis. J Parasitol (1994) 2.36
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
Crystal structures of medium-chain acyl-CoA dehydrogenase from pig liver mitochondria with and without substrate. Proc Natl Acad Sci U S A (1993) 2.29
Retrieval of water-leaving radiance and aerosol optical thickness over the oceans with SeaWiFS: a preliminary algorithm. Appl Opt (1994) 2.28
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Error-free and error-prone lesion bypass by human DNA polymerase kappa in vitro. Nucleic Acids Res (2000) 2.25
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol (2000) 2.18
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Fractal model of ion-channel kinetics. Biochim Biophys Acta (1987) 2.17
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 2.14
The fate of interleukin-2 after in vivo administration. J Immunol (1983) 2.13
Specificity of DNA lesion bypass by the yeast DNA polymerase eta. J Biol Chem (2000) 2.12